Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2021 | Novel targets and the future role of combinations for myeloma

Leo Rasche • 14 Jun 2021
EHA 2021
Multiple Myeloma Antibodies

Leo Rasche, MD, University of Arkansas for Medical Sciences, Little Rock, AR, gives a brief overview of novel targets for the treatment of multiple myeloma and talks on the potential of targeting GPRC5D and FCRH5, as well as highlighting the key role of combination approaches in the future. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Leo Rasche

Novel targets in multiple myeloma & the role of the immune system in disease progression
9:26
Novel targets in multiple myeloma & the role of the immune system in disease progression
Leo Rasche • 12 Apr 2025
Using spatial transcriptomics to study focal lesions in multiple myeloma
4:06
Using spatial transcriptomics to study focal lesions in multiple myeloma
Leo Rasche • 30 Jan 2025
Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patients
2:18
Evolving treatment options in NDMM: transplant-eligible and transplant-ineligible patients
Leo Rasche • 28 Sep 2023
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma
1:47
WGS reveals sequential & persistent loss of BCMA and GPRC5D after bispecific antibodies in myeloma
Leo Rasche • 28 Sep 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Leo Rasche • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Leo Rasche • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Leo Rasche • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Leo Rasche • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals